No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin

Podobne zapisy

• Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study
  od: Frey, Reiner, i wsp.
  Wydane: (2016)
• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  od: Frey, Reiner, i wsp.
  Wydane: (2009)
• Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality
  od: Becker, Corina, i wsp.
  Wydane: (2016)
• Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  od: Frey, Reiner, i wsp.
  Wydane: (2016)
• Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  od: Frey, Reiner, i wsp.
  Wydane: (2016)